Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

CEPHALON, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

Nine Months Ended

September 30,

2008 2007

CASH FLOWS FROM OPERATING ACTIVITIES:

Net income (loss) $210,962 $(235,886)

Adjustments to reconcile net

income to net cash provided by

operating activities:

Deferred income tax

(benefit) expense (9,409) 8,750

Shortfall tax benefits from

stock-based compensation (451) (222)

Depreciation and amortization 128,772 101,206

Stock-based compensation expense 32,543 34,940

Gain on sale of investment - (5,791)

Gain on forgiveness of debt - (5,319)

Loss on disposals of property

and equipment 2,740 2,873

Impairment charges 1,164 -

Other (396) 180

Changes in operating

assets and liabilities:

Receivables (74,258) (26,218)

Inventory (14,557) (1,881)

Other assets (99,008) (28,552)

Accounts payable and

accrued expenses 34,526 380,776

Other liabilities 70,
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Decision Resources Group finds that the Latin ... percent compound annual growth rate through 2023. This is ... the increasing adoption of dental implants. Growing aesthetic consciousness ... spur demand for dental biomaterials because they can improve ... Other key findings from Decision Resources Group,s ...
(Date:12/19/2014)... 2014 BioPlus Specialty Pharmacy ... pharmacies, has an expanded team of Regional Pharmaceutical ... for prescriber offices in their regions, with specific ... have a variety of Regional Pharmaceutical Care Liaisons ... in hepatitis C help prescribers understand all the ...
(Date:12/19/2014)... December 18, 2014 LayerBio is an ... and wound care. The National Eye Institute (NEI) at ... a Phase I SBIR grant to develop a drug-eluting ... the most common cause of vision loss in people ... worldwide. According to Dr. Ken Mandell, LayerBio’s Founder and ...
(Date:12/19/2014)... Reports from CDC show ... from one or more chronic health conditions - including ... address some of these diseases, but may not eliminate ... face. While implanted nerve stimulation devices today offer relief, ... which can induce side effects. , To eliminate ...
Breaking Biology Technology:Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2
... this week,s PLoS Medicine , Luis Montaner from ... a potential capacity-saving CD4 count model to a cohort ... suggest that the model could be used to optimize ... authors stress that the method is not intended to ...
... ago, the Dutch theoretical physicist Hendrik Casimir calculated that ... would attract. The mysterious force arises from the energy ... as described by quantum theory. Now Norio Inui, a ... predicted that in certain circumstances a reversal in the ...
... April 18, 2012 SeraCare Life Sciences, Inc. (NASDAQ: ... providing vital products and services to facilitate the discovery, ... that, at a special meeting of shareholders held today, ... Project Plasma Holdings Corporation and Project Plasma Merger Corp., ...
Cached Biology Technology:SeraCare Shareholders Approve Acquisition by Linden Capital Partners 2SeraCare Shareholders Approve Acquisition by Linden Capital Partners 3
(Date:12/10/2014)... , Dec. 08, 2014 Research and ... the addition of the "Biometrics Market in ... http://photos.prnewswire.com/prnh/20130307/600769 ... projects such as rural banking and upgradation of ... trends witnessed in the market. Besides the aforementioned ...
(Date:12/5/2014)... MOUNTAIN VIEW, Calif. , Dec. 4, 2014 ... and safety has boosted investments in new testing ... products has also given rise to a range ... driven by the requirements of Generation Y, which ... digital technologies. As a result, product development strategies ...
(Date:12/4/2014)... BEACH GARDENS, Fla. , Dec. 3, 2014 ... management solutions, today announced that its DigitalPersona ® ... 4500 fingerprint readers have been deployed throughout First ... , South Carolina ... headquartered in Southern Pines, North Carolina ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... have identified the first major gene location responsible for ... eosinophilic esophagitis (EoE). In this disease, which may cause ... may be unable to eat a wide variety of ... study team found EoE was linked to a region ...
... (ASM) Promega Biotechnology Research Award will be presented ... Medicine and Genome Sciences, University of Washington, Seattle, ... Corporation, this award honors outstanding contributions to the ... development. Olson realized the study of ...
... available in French . , Dr. Marc ... Anatomy and Cell Biology, is collaborating closely with Enobia Pharma ... serious genetic bone diseases. McKee,s research looks into the reasons ... bones and teeth. While osteoporosis later in life is an ...
Cached Biology News:Gene site found for children's food allergy 2American Society for Microbiology honors Maynard V. Olson 2McGill, Quebec biotech firm partner for new bone-disease treatment 2
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
Experion Pro260 chips are the microfluidic chips used to perform protein analysis with the Experion automated electrophoresis system. Each chip has the capacity to run 10 protein samples. Supplied as...
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
Biology Products: